Astute Medical is a San Diego-based diagnostics company that developed NephroCheck, a biomarker test for acute kidney injury (AKI). Last month the company won 510(k) clearance from the FDA for NephroCheck, which is used to test for AKI in patients following serious cardiac or respiratory events. NephroCheck will be marketed by Ortho-Clinical Diagnostics. Astute is positioned to receive up to $30 million under a standing loan agreement with funding partner CRG to commercialize NephroCheck, plus an additional $10 million if it hits certain revenue milestones. Its most recent disclosed financing prior to this was a $40.4 million Series C in 2012 led by MPM Capital and the venture arms of Johnson & Johnson and Kaiser Permanente. The company indicated plans to have representatives at the 2014 CVT Critical Care conference in Washington. Astute Medical, based in San Diego, develops novel biomarker-based medical diagnostics. The company is led by CEO Christopher Hibberd. It focuses on rapid diagnosis and risk assessment for community- and hospital-acquired acute conditions, including abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. The company plans to begin commercializing its first product and to advance and expand research, development and validation of biomarker-based laboratory tests. The recent financing is intended to fund those commercialization and R&D efforts. Astute Medical is a San Diego company dedicated to identifying and validating protein biomarkers as the basis for novel diagnostic laboratory tests. Its core work centers on biomarker discovery, research, development and clinical validation for rapid diagnosis and risk assessment. The company focuses on community- and hospital-acquired acute conditions, with current areas of interest that include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. In August 2011 it completed a $13M financing as an extension of its Series B round. The transaction involved the sale of additional Series B shares to existing stockholders, and the proceeds are intended to advance and expand its R&D and validation efforts. No operating metrics (revenue/users) were reported in the article. Astute Medical is a San Diego, California–based developer of novel, biomarker-based medical diagnostics focused on protein biomarkers. The company aims to identify and validate protein biomarkers to commercialize high‑potential diagnostic products. Current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Management says it will use new capital to advance research and development and to conduct clinical studies that move products closer to commercialization. Astute Medical was founded in 2007 and is led by Christopher Hibberd and Paul McPherson, Ph.D., who were formerly members of management at Biosite Incorporated. The company completed a Series B to support these development and clinical efforts.

Total raised

$110M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Oct 2014